Karl J. Puttlitz

Array ( [id] => 14567009 [patent_doc_number] => 20190211111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Switchable antibody conjugate [patent_app_type] => utility [patent_app_number] => 16/208768 [patent_app_country] => US [patent_app_date] => 2018-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16208768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14156401 [patent_doc_number] => 20190105303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => PHARMACEUTICAL COMBINATIONS [patent_app_type] => utility [patent_app_number] => 16/208172 [patent_app_country] => US [patent_app_date] => 2018-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16208172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16304199 [patent_doc_number] => 10772970 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Glucocorticoid receptor agonist and immunoconjugates thereof [patent_app_type] => utility [patent_app_number] => 16/204825 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14070 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16204825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16939870 [patent_doc_number] => 11052085 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-06 [patent_title] => Methods for treating skeletal muscle cachexia arising from burn injury by administering PDE4B-selective inhibitors [patent_app_type] => utility [patent_app_number] => 16/202878 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 5152 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16202878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555823 [patent_doc_number] => 20210000971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => FUSION PROTEIN COMPRISING GLUTATHIONE-S-TRANSFERASE AND PROTEIN HAVING BINDING AFFINITY TARGET CELL OR TARGET PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/767804 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12086 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649529 [patent_doc_number] => 20190231893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/195384 [patent_app_country] => US [patent_app_date] => 2018-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16195384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596602 [patent_doc_number] => 20210023133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => MULTIFUNCTIONAL IMMUNE CELL THERAPIES [patent_app_type] => utility [patent_app_number] => 16/763776 [patent_app_country] => US [patent_app_date] => 2018-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310922 [patent_doc_number] => 20200289660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => PYRROLOBENZODIAZEPINE CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/763814 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14563907 [patent_doc_number] => 20190209560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => MNK INHIBITORS AND METHODS RELATED THERETO [patent_app_type] => utility [patent_app_number] => 16/178678 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14372353 [patent_doc_number] => 20190160089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => COMBINATION TREATMENT WITH ANTIBODY-DRUG CONJUGATES AND CYTARABINE [patent_app_type] => utility [patent_app_number] => 16/175165 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16175165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17755518 [patent_doc_number] => 11395796 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Anti-CD37 immunoconjugate and anti-CD20 antibody combinations [patent_app_type] => utility [patent_app_number] => 16/170160 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 28805 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16549766 [patent_doc_number] => 10882915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Compositions and methods for the depletion of CD117+ cells [patent_app_type] => utility [patent_app_number] => 16/168816 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 45 [patent_no_of_words] => 53550 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 1111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16168816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590593 [patent_doc_number] => 10899843 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Compositions and methods for the depletion of CD117+ cells [patent_app_type] => utility [patent_app_number] => 16/168823 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 52 [patent_no_of_words] => 57210 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16168823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982633 [patent_doc_number] => 20190060474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 16/162158 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 372 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16162158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18978771 [patent_doc_number] => 11903925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-20 [patent_title] => Compositions for preventing and treating pulmonary injury due to ionizing radiation or cytotoxic drugs [patent_app_type] => utility [patent_app_number] => 16/162222 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6650 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16162222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15631897 [patent_doc_number] => 10588916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Technology to inhibit vascular changes that lead to vision loss in the eye [patent_app_type] => utility [patent_app_number] => 16/160840 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 34 [patent_no_of_words] => 31026 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16160840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14182891 [patent_doc_number] => 20190111150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/159559 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19915225 [patent_doc_number] => 12290571 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Programmable dendritic drugs [patent_app_type] => utility [patent_app_number] => 16/639499 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16850 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 471 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901591 [patent_doc_number] => 20190040000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/153193 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16153193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696711 [patent_doc_number] => 10604522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Processes for producing diazabicyclooctane compounds [patent_app_type] => utility [patent_app_number] => 16/148774 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 22187 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148774 [rel_patent_id] =>[rel_patent_doc_number] =>)